EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treosulfan/Fludarabine as conditioning regimen for allogeneic stem cell transplantation in multiple myeloma



Treosulfan/Fludarabine as conditioning regimen for allogeneic stem cell transplantation in multiple myeloma



Blood 102(11): 711a, November 16



While autologous stem cell transplantation (PBSCT) is considered as standard approach to treat multiple myeloma (MM), it does not offer definite cure from the disease. Curative potential is ascribed to allogeneic PBSCT, however, this procedure is reported to be highly toxic whenever "classical" myeloablative regimens are used for conditioning. Therefore, toxicity-reduced regimens are needed which allow patients with MM to proceed to allogeneic PBSCT. Treosulfan (L-Threitol 1,4-Bismethanesulfonate), a bifunctional alkylating agent, has shown efficacy against a variety of malignancies. It exhibits myeloablative potential making it suitable as preparative drug for transplantation. We first assessed the feasibility of a fix dose of 3X10 g/m2 Treosulfan i.v. combined with 5X30 mg/m2 Fludarabine for conditioning. Then, we started a dose-escalating study with Treosulfan 3X10 g/m2, 3X12 g/m2, and 3X14 g/m2, combined with Fludarabine 5X30 mg/m2, respectively. Out of 86 patients (pts) with various hematological malignancies included into the two trials, 16 pts suffered from MM. Twelve pts had a matched-related donor, the other 4 pts had a matched-unrelated donor. At time of this analysis, 15 out of the 16 pts are evaluable with respect to relapse/progression rate, mortality rate and survival data. All of them (median age 52 years, range 48-61) were heavily pretreated including 9 pts who had undergone prior autologous PBSCT. Conditioning was well tolerated, and all pts engrafted. Three relapses occurred at day 172, day 256 and 470 after PBSCT, respectively, while median progression-free survival is not reached so far. Two deaths were reported. One was due to cardiac amyloidosis on day 62 after transplantation, the other was related to severe infection on day 713. Considering the relatively limited observation time, median overall survival is 223+ days (range 13-1008). In summary, the combination of Treosulfan and Fludarabine appears to be a suitable regimen to prepare pts with MM for allogeneic PBSCT. While the optimal Treosulfan dose is currently defined, this regimen showed a promising low toxicity profile and so far a low relapse/progression rate. It therefore may permit even heavily pretreated pts with MM to proceed to allogeneic PBSCT and to pursue the curative goal of treatment.

(PDF 0-2 workdays service: $29.90)

Accession: 035985739

Download citation: RISBibTeXText



Related references

Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation. Blood 103(2): 725-731, 2003

Allogeneic hematopoietic stem cell transplantation after treosulfan/fludarabine conditioning in high-risk patients with hematologic malignancies Dose escalation of treosulfan. Blood 102(11): 467a, November 16, 2003

Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. American Journal of Hematology 83(9): 717-720, 2008

Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation. Annals of Hematology 83 Suppl 1: S70-S71, 2004

Toxicity reduced conditioning with treosulfan and fludarabine for allogeneic blood stem cell transplantation. Onkologie 23(Sonderheft 7): 120, October, 2000

Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine. Deutsche Medizinische Wochenschrift 130(38): 2125-2129, 2005

Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine. European Journal of Haematology 88(1): 87-88, 2012

Toxicity-reduced conditioning with treosulfan and fludarabine prior to allogeneic blood stem cell transplantation. Blood 96(11 Part 2): 298b, November 16, 2000

Thiotepa, Fludarabine and Melphalan, a Reduced-Dose Regimen for Allogeneic Haematopoietic Stem Cell Transplantation in Multiple Myeloma. Blood 100(11): Abstract No 5290, November 16, 2002

Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia. British Journal of Haematology 142(2): 284-292, 2008

Influence of timing allogeneic stem cell transplantation after dose-reduced melphalan/fludarabine conditioning in multiple myeloma. Blood 102(11): 728a, November 16, 2003

Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of Hematology 86(8): 583-589, 2007

Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. Journal of Clinical Oncology 28(20): 3344-3351, 2010

Dose-reduced conditioning with treosulfan/fludarabine followed by allogeneic stem cell transplantation from related and unrelated donors in patients with AML and MDS/sAML. Blood 102(11): 334b, November 16, 2003

The treatment of multiple myeloma with an allogeneic peripheral blood stem cell transplantation using a non-myeloablative conditioning regimen. Vnitrni Lekarstvi 46(7): 377-383, 2005